Share Name Share Symbol Market Type Share ISIN Share Description
Amphion Innovations LSE:AMP London Ordinary Share GB00B0DJNP99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.125p +11.11% 1.25p 1.00p 1.50p 1.25p 1.125p 1.125p 0 09:24:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.1 -13.6 -7.3 - 2.59

Amphion (AMP) Latest News

More Amphion News
Amphion Takeover Rumours

Amphion (AMP) Share Charts

1 Year Amphion Chart

1 Year Amphion Chart

1 Month Amphion Chart

1 Month Amphion Chart

Intraday Amphion Chart

Intraday Amphion Chart

Amphion (AMP) Discussions and Chat

Amphion (AMP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Amphion trades in real-time

Amphion (AMP) Top Chat Posts

DateSubject
21/11/2017
08:20
Amphion Daily Update: Amphion Innovations is listed in the General Financial sector of the London Stock Exchange with ticker AMP. The last closing price for Amphion was 1.13p.
Amphion Innovations has a 4 week average price of 1.13p and a 12 week average price of 1.13p.
The 1 year high share price is 4.75p while the 1 year low share price is currently 1.13p.
There are currently 207,511,229 shares in issue and the average daily traded volume is 467,266 shares. The market capitalisation of Amphion Innovations is £2,593,890.36.
15/11/2017
16:45
hoggar: Confidence is the optimal word with this company. It’s no wonder Amphion cannot attract funding while its share price in firmly classified as junk status. Amphion directors primary task is to secure funding for partner companies. It would appear Amphion had no input with the fund raising Motif has just secured. I think that just about says it all with this outfit.
15/11/2017
15:32
escapetohome: No confidence whatsoever in this company, not one shred, and the share price reflects my opinion.
02/11/2017
09:06
hoggar: I posted here recently the implications and the improbability of Amphion gaining any favourable Federal judgement from the 402 and 502 Microstrategy case. In other words Amphion have run out of money and these patents are now worthless from December 2017. In brief, Amphion have spent millions and borrowed millions employing useless inept so-called patent lawyers in the states fighting SAP, Microsoft etc for many years. There is no doubt the patents were valid but now they are not! So today’s announcement that Amphion will continue to explore further means of funding and borrowing to pursue more litigation is totally ridiculous. This announcement also indicates that Amphion will use any profits from the share price in Motif and Polareon to fund further borrowing. Investors need to consider if this bunch of mindless directors at Amphion are of sound mind.
04/10/2017
09:10
debbie_does_dallas_twice: Look at the facts and not dagenham dave's bitter spiteful deramps.. The shares now have a circa value of 5p with mtfb at 50p Financial Results (note how a 4p recovery on mtfb changed the nav by 1.4p.) this was when the price was 31p). -- Net Asset Value ("NAV") per share was -1p (US -$0.02 cents)* at Period-end from -2.4p (US -$0.03 cents) as at year end. This increase was due almost entirely to the movement in value of the Motif Bio plc share price Highlights Amphion
04/10/2017
08:52
bullet ant: That was before mtfb price up nearly 40% today Financial Results -- Net Asset Value ("NAV") per share was -1p (US -$0.02 cents)* at Period-end from -2.4p (US -$0.03 cents) as at year end. This increase was due almost entirely to the movement in value of the Motif Bio plc share price Highlights Amphion -- Sold the Company's remaining holding of Kromek Group plc -- Richard Morgan and Robert Bertoldi, Directors of the Company, entered into a Deed of Postponement where they agreed to postpone the repayment of the amounts owed to them, which total US $4.3 million, until all other debts of the Company are repaid Motif Bio -- In January, Motif Bio completed treatment of patients in its Phase III trial (REVIVE-1) for its product candidate iclaprim -- In April, Motif Bio released data readout from REVIVE-1, showing iclaprim to be well tolerated and met the non-inferiority margin mandated by the FDA Polarean
04/10/2017
08:52
tomboyb: Yeah - I think there is a lot of work to do here hence the current share price - So it is a small punt only from me -
10/4/2017
21:36
sorksandnorks: Is something up? The share price certainly is! Is anyone aware of anything relevant or is it just another false dawn?
12/8/2016
15:11
123prezzie: About MTFB. A post says that the 'main holder' is supporting the NASDAQ fund raising but doesn't say who this is. If it is AMP, who held 26% at 31/12/15, then I suggest that the meaning of 'support' needs to be defined. AMP appears to be pretty short of cash and has already pledged well over half its MTFB shares as collateral against loans charging 10% (!) interest. The latest tranche is covered by the RNS above dated 18/7/16 where AMP has borrowed $750,000 with 1.4m MTFB shares as security ie an implied value of about 42p/share. Followers of Quindell and similar will know that the way these deals usually work is that the lender, probably with the benefit of a Put arrangement, sells if the share price falls near 42p, thus recouping the loan. MTFB is unlikely to survive for many months unless it can convince investors that its products will be successful. I strongly recommend that any investor, actual or potential, should read the AMP and MTFB accounts and then tell me if/where I am wrong. Also note that AMP has just sold some of its Kromek shares. No further comment
23/6/2015
11:11
dlm2602: timbo003.... Not sure about your maths. AMP holds 28.3m shares in MTFB. A 5p increase in MTFB share price adds £1.41m to the NAV of AMP. There are currently around 197m shares in AMP. An increase of £1.41m in NAV equates to rise of just 0.7p, or in other words a 7p increase in MTFB should increase the NAV of AMP by 1p. In any event AMP is still a good way into MTFB imho.
14/6/2015
09:39
shackleton1: Kromek tipped in The Sunday Mail. This will be good for the AMP share price tomorrow.
Amphion share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171121 14:07:29